- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response.
EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer
EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
EP: 6.Exploring Results from CAPItello-291 Trial
EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer
EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook
EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts
- Abemaciclib has been integrated into the NCCN Guidelines for certain patients with high-risk early-stage disease. What data is needed for ribociclib to find a similar position in the guidelines?
- What are the guideline recommendations for monitoring for response to systemic treatment in breast cancer? What outcomes are most important when monitoring response to treatment?
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
